<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102509">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01903460</url>
  </required_header>
  <id_info>
    <org_study_id>LUM001-302</org_study_id>
    <secondary_id>2012-005346-38</secondary_id>
    <nct_id>NCT01903460</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome</brief_title>
  <acronym>IMAGO</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Paediatric Patients With Alagille Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lumena Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lumena Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomized, double-blind, placebo-controlled study to evaluate the safety and
      tolerability of LUM001.  Efficacy will be assessed by evaluating the effect of LUM001 versus
      placebo on the biochemical markers and pruritus associated with Alagille Syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>13 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in fasting serum bile acids compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>13 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in liver enzymes and pruritus compared to placebo</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>13  weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluation of adverse events, changes in vital signs, laboratory and other safety parameters</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Alagille Syndrome</condition>
  <arm_group>
    <arm_group_label>LUM001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LUM001 administered orally once each day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally once each day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LUM001</intervention_name>
    <arm_group_label>LUM001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of Alagille Syndrome

          2. Evidence of cholestasis

          3. Moderate to severe pruritus

          4. Ability to understand and willingness to sign informed consent/assent prior to
             initiation of any study procedures

        Exclusion Criteria:

          1. Surgical disruption of the enterohepatic circulation

          2. Liver transplant

          3. History or presence of other concomitant liver disease

          4. Females who are pregnant or lactating

          5. Known HIV infection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alejandro Dorenbaum, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lumena Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Barbat, BSN, RN</last_name>
    <phone>858-461-0694</phone>
    <email>info@lumenapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Lloyd</last_name>
      <email>carla.lloyd@bch.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Gemma Slinn</last_name>
      <email>Gemma.slinn@bch.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Deirdre Kelly, FRCPI, FRCP,FRCPCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Ashton</last_name>
      <email>sarah.ashton@cmft.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Nicola Balatoni</last_name>
      <email>nicola.balatoni@leedsth.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Patricia McClean, MD,FRCP,FRCPCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Palaniswamy Karthikeyan</last_name>
      <email>pkarthikeyan@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Harpreet Grewal</last_name>
      <email>harpreet.grewal@kcl.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Alastair Baker, MBChB,FFARCS,MRCP,FRCPCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.lumenapharma.com</url>
  </link>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>April 3, 2014</lastchanged_date>
  <firstreceived_date>July 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Alagille Syndrome</mesh_term>
    <mesh_term>Cholestasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
